92547-10-9

Basic information

• Product Name: 1,3-Propanediamine, N'-(5-chloro-2-nitrophenyl)-N,N-dimethyl-
• CAS NO: 92547-10-9
• Molecular Formula: C11H16ClN3O2
• Molecular Weight: 257.72
• Mol File: 92547-10-9.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 1,3-Propanediamine, N'-(5-chloro-2-nitrophenyl)-N,N-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,3-Propanediamine, N'-(5-chloro-2-nitrophenyl)-N,N-dimethyl-(92547-10-9)
• EPA Substance Registry System: 1,3-Propanediamine, N'-(5-chloro-2-nitrophenyl)-N,N-dimethyl-(92547-10-9)

Safety Data

• Hazardous Substances Data: 92547-10-9(Hazardous Substances Data)

Upstream product

• 611-06-3 2,4-dichloronitrobenzene 
• 109-55-7 1-amino-3-(dimethylamino)propane 
• 700-37-8 4-chloro-2-fluoro-nitrobenzene 

Downstream Products

• 1616475-69-4 N³-(3-(dimethylamino)propyl)-4-nitro-N¹-(pyridin-3-yl)benzene-1,3-diamine 
• 1616475-72-9 N-(1-(3-(dimethylamino)propyl)-6-(pyridin-4-ylamino)-1H-benzo[d]imidazol-2-yl)benzamide 
• 1616475-71-8 N-(1-(3-(dimethylamino)propyl)-6-(pyridin-3-ylamino)-1H-benzo[d]imidazol-2-yl)benzamide 
• 1616475-68-3 N³-(3-(dimethylamino)propyl)-4-nitro-N¹-(pyridin-4-yl)benzene-1,3-diamine 
• 600725-16-4 4-chloro-N₂-(3-dimethylaminopropyl)-benzene-1,2-diamine 

Relevant articles and documents

Aryl-substituted aminobenzimidazoles targeting the hepatitis C virus internal ribosome entry site

We describe the exploration of N1-aryl-substituted benzimidazoles as ligands for the hepatitis C virus (HCV) internal ribosome entry site (IRES) RNA. The design of the compounds was guided by the co-crystal structure of a benzimidazole viral translation inhibitor in complex with the RNA target. Structure-binding activity relationships of aryl-substituted benzimidazole ligands were established that were consistent with the crystal structure of the translation inhibitor complex.

Indole RSK inhibitors. Part 2: Optimization of cell potency and kinase selectivity

A series of inhibitors for the 90 kDa ribosomal S6 kinase (RSK) based on an 1-oxo-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a]indole-8-carboxamide scaffold were optimized for cellular potency and kinase selectivity. This led to the identification of compound 24, BIX 02565, an attractive candidate for use in vitro and in vivo to explore the role of RSK as a target for the treatment heart failure.

Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof

The present invention relates to substituted piperidines of general formula wherein R, R2 to R5, A, X, Z and n are defined as in claim 1, the tautomers, diastereomers, enantiomers, mixtures and salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, the use thereof and processes for the preparation thereof.